New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure

Study data also show that using certain DecisionDx-Melanoma test results in conjunction with current guidelines can reduce the number of SLNB procedures performed, particularly in patients with a low... | October 20, 2022

Related Keywords

United Kingdom ,Edgewood ,Kentucky ,United States ,Edinburgh ,City Of ,Castle Biosciences ,J Michael Guenther ,Instagram ,Linkedin ,Castle Biosciences Inc ,Twitter ,Nasdaq ,International Congress ,Securities Exchange ,Facebook ,Society For Melanoma Research ,Elizabeth Physicians ,Melanoma Research ,About Decisiondx ,Mypath Melanoma ,Securities Act ,Securities Exchange Act ,Quarterly Report ,Decisiondx Melanoma Impact ,Sentinel Lymph Node Biopsy Decisions ,Clinical Outcomes ,Clinical Risk Factors ,Sentinel Lymph Node Biopsy ,Thin Melanoma ,Systematic Review ,Nc Stock Exchange ,News ,Information ,Press Release ,Study ,Data ,Also ,Show ,Hat ,Sing ,Certain ,Pest ,Results ,N ,Conjunction ,Ith ,Current ,Guidelines ,Han ,Educe ,The ,Number ,F ,Klnb ,Procedures ,Particularly ,Patients ,Ith Cstl Us14843c1053 ,